HUGEL INC
BiotechHUGEL INC is a biotechnology company focused on Dermatology.
FDA Novel Drug Designations
(2024)See 1 novel approval →
HUGEL INC at a Glance
- Strong track record with 95% execution quality across 14 trials
- Fast trial execution (15 months median completion)
HUGEL INC's Key Drugs
HUGEL INC's core commercial portfolio centers on LETYBO, spanning Dermatology — its most strategically important drugs approved in the last 15 years.
HUGEL INC's Recent FDA Approvals
New NDA/BLA approvals for HUGEL INC over the last two years — novel drugs only, excluding generics and label supplements.
HUGEL INC's Therapeutic Areas
HUGEL INC's approved drugs and pipeline span 1 therapeutic area, led by Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HUGEL INC's Top Competitors
HUGEL INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HUGEL INC Pipeline Snapshot
HUGEL INC has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LETYBO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 7/7 completed
- • Speed: 15 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2024-02-29
- Latest
- 2024-02-29
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges